Pfizer is undertaking several initiatives to advance awareness, understanding, and treatment of sickle cell disease (SCD). Pfizer is evaluating an investigational drug to determine if it can reduce the time spent in the hospital and the need for opioid pain relievers during severe sickle cell pain episodes. Pfizer is screening more than 4,500 babies for SCD. The aim is to build a model ecosystem of care, with the screening program serving as a model for other hospitals across Ghana and sub-Saharan Africa. Pfizer acquired Global Blood Therapeutics (GBT) in 2022. Pfizer is conducting Phase 3 trials to evaluate the efficacy and safety of reducing vaso-occlusive crises in SCD patients. Pfizer is also developing another investigational SCD drug , which is currently in Phase 2 clinical trials. Through these initiatives, Pfizer is actively working to raise awareness, improve screening and diagnosis, and develop new treatments for sickle cell disease